66 related articles for article (PubMed ID: 17259129)
1. [Half-dose Zenapax for acute rejection prevention after renal transplantation].
Zhu YS; Xu AP; He HX; Fan LP; Nie HB; Nv J; Hu WN; Li QR; Deng ZX
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec; 26(12):1818-20. PubMed ID: 17259129
[TBL] [Abstract][Full Text] [Related]
2. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of three-dose regimen of Zenapax in orthotopic liver transplantation].
He G; Yu LX; Deng WF
Di Yi Jun Yi Da Xue Xue Bao; 2004 Jul; 24(7):729-32. PubMed ID: 15257886
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation.
Ciancio G; Gaynor JJ; Roth D; Kupin W; Hanson L; Tueros L; Zarak A; Ruiz P; Burke GW
Transplant Proc; 2010 Nov; 42(9):3503-6. PubMed ID: 21094804
[TBL] [Abstract][Full Text] [Related]
5. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
Ekberg H; Bäckman L; Tufveson G; Tydén G
Transplant Proc; 1999; 31(1-2):267-8. PubMed ID: 10083102
[No Abstract] [Full Text] [Related]
6. [MMF and CyA in the prevention of early acute rejection after renal transplantation].
He B; Han X; Liu J; Han Z; Guan D; Gao J
Zhonghua Wai Ke Za Zhi; 2000 Sep; 38(9):683-5. PubMed ID: 11832139
[TBL] [Abstract][Full Text] [Related]
7. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of three induction antibodies in kidney transplantation: long-term results.
Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Chen L; Mattiazzi A; Roth D; Kupin W; Tueros L; Flores S; Hanson L; Vianna R; Burke GW
Transplantation; 2014 Jun; 97(11):1128-38. PubMed ID: 24477186
[TBL] [Abstract][Full Text] [Related]
9. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
Kandus A; Grego K; Bren AF
Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
[TBL] [Abstract][Full Text] [Related]
10. [Anti interleukin-2 receptor alpha antibodies (daclizumab) application for the treatment of kidney recipients].
Izvolskaja N; Rainiene T; Dainys B
Medicina (Kaunas); 2003; 39 Suppl 1():166-70. PubMed ID: 12761441
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of rejection after simultaneous pancreas-kidney transplantation.
Yang L; Liu YF; Liu SR; Wu G; Zhang JL; Meng YM; Shong SW; Li GC
Chin Med Sci J; 2005 Sep; 20(3):210-3. PubMed ID: 16261897
[TBL] [Abstract][Full Text] [Related]
12. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
[TBL] [Abstract][Full Text] [Related]
14. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
Roodnat JI; Hilbrands LB; Hené RJ; de Sévaux RG; Smak Gregoor PJ; Kal-van Gestel JA; Konijn C; van Zuilen A; van Gelder T; Hoitsma AJ; Weimar W
Transplantation; 2014 Jul; 98(1):47-53. PubMed ID: 24521775
[TBL] [Abstract][Full Text] [Related]
15. [Individual immunosuppressive regime in heart transplantation with high risk].
Wu XJ; Chen LW; Chen DZ; Huang XS; Cao H
Zhonghua Wai Ke Za Zhi; 2008 Jun; 46(11):820-2. PubMed ID: 19035214
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
[TBL] [Abstract][Full Text] [Related]
17. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
18. [Long-term therapeutic effect of Zenapax after renal transplantation].
Liu W; Ling JY
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2565-7. PubMed ID: 20137620
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
